Screening & Evaluation of Diuretics

Screening & Evaluation of Diuretics

1. Definition, scope & rationale

• Diuretic = an agent that increases the rate of urine formation, thereby increasing the net renal excretion of water and (usually) solute; the experimental task of screening is to detect this activity in a test compound, while evaluation quantifies its potency, electrolyte profile, onset, duration, and ceiling (Vogel 4e V1 Part III, pp.835–840; Medhi Ch.29, pp.303–307).
• Screening asks the qualitative/quantitative question: does compound X have diuretic activity, and how strong? — typically a first-pass, high-throughput, in-vivo rodent assay (the Lipschitz test) backed by an in-vitro mechanistic assay (carbonic-anhydrase inhibition) (Vogel 4e V1 Part III, pp.835–838).
• Evaluation asks the characterising questions: what is the electrolyte signature (saluretic, natriuretic, kaliuretic, K⁺-sparing, carbonic-anhydrase-inhibitory)? what is the onset, peak, duration and dose–response slope? where in the nephron does it act? — answered by the saluretic-index rat assay and the catheterised-dog assay (Vogel 4e V1 Part III, pp.839–840).
• Excretion of salt and water is therapeutically central to oedema of congestive heart failure, ascites, and hypertension; a good screen must therefore measure both the aquaretic (water) and the saluretic (electrolyte) components, because clinically useful diuretics act mainly through natriuresis with secondary water loss (Vogel 4e V1 Part III, p.839; Medhi Ch.29, p.305).
• Distinct from clinical diuretic pharmacology — this topic is the bench/preclinical screening-method PYQ: how a novel candidate is tested in isolated enzyme, rat, and dog systems and in healthy human volunteers, not the clinical use of furosemide/thiazides in patients (Vogel 4e V1 Part III, pp.835–841).
• Validity anchor (positive controls): every screening cascade is run with reference diuretics of known class so the assay's discriminating power is verifiable — furosemide / bumetanide / piretanide (loop/high-ceiling), hydrochlorothiazide (thiazide), acetazolamide / chlorothiazide (carbonic-anhydrase inhibitor), triamterene / amiloride (K⁺-sparing Na⁺-channel blockers), spironolactone (aldosterone antagonist) (Vogel 4e V1 Part III, pp.836–838, 839, 840).